Literature DB >> 27815867

Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

Steven Xu1, Peter De Porre2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27815867     DOI： 10.1007/s40262-016-0469-1

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  11 in total

1.  Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

Authors:  Nuggehally R Srinivas
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

2.  Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Xu Steven Xu; Charles J Ryan; Kim Stuyckens; Matthew R Smith; Fred Saad; Thomas W Griffin; Youn C Park; Margaret K Yu; Peter De Porre; An Vermeulen; Italo Poggesi; Partha Nandy
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

3.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

4.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

Authors:  Daniel C Danila; Michael J Morris; Johann S de Bono; Charles J Ryan; Samuel R Denmeade; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Thian Kheoh; Christopher Haqq; Arturo Molina; Aseem Anand; Michael Koscuiszka; Steve M Larson; Lawrence H Schwartz; Martin Fleisher; Howard I Scher
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Authors:  Charles J Ryan; Matthew R Smith; Lawrence Fong; Jonathan E Rosenberg; Philip Kantoff; Florence Raynaud; Vanessa Martins; Gloria Lee; Thian Kheoh; Jennifer Kim; Arturo Molina; Eric J Small
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

8.  Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Authors:  Kim Stuyckens; Fred Saad; Xu Steven Xu; Charles J Ryan; Matthew R Smith; Thomas W Griffin; Margaret K Yu; An Vermeulen; Partha Nandy; Italo Poggesi
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

9.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Authors:  Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

10.  Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Authors:  Zhenfei Li; Andrew C Bishop; Mohammad Alyamani; Jorge A Garcia; Robert Dreicer; Dustin Bunch; Jiayan Liu; Sunil K Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.